Aureus Pharma licenses AurSCOPE Ion Channel Knowledgebase to Xention
Aureus Pharma announces that Xention, a drug discovery and development company focusing on ion channels, has licensed its AurSCOPE Ion Channel Knowledge database.
Ion Channels are an important drug target class as they are involved in many physiological and pathophysiological processes, including cardiac arrhythmias, auto-immune diseases, pain, multiple sclerosis and over active bladder. AurSCOPE Ion Channel is a comprehensive knowledge database containing detailed biological activity that has been described in journals and patents for all known ion channels and their ligands.
"We will use the data contained in the AurSCOPE Ion Channel knowledgebase in combination with our in-house proprietary technology and databases to accelerate the discovery of novel small molecules" said Dr. Dave Madge, Xention´s Vice President of Chemistry. "Access to this knowledge database will help us to use the selectivity profile and ADMET properties of existing drugs to design better molecules for our ion channel targets."
"We are delighted that Xention, an ion channel specialist, has chosen Aureus´ ion channel knowledge database," said Dr. André Michel of Aureus Pharma. "We are confident that the high quality data will complement Xention´s drug discovery platform."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Revvity broadens relationship with Genomics England to advance genomics in the UK - Collaborating for better baby health
BioXell Initiates Phase IIb Trial of BXL628 in Benign Prostatic Hyperplasia

Activation of opioid receptor uncovered
Lipid_bilayer
Jazz Pharmaceuticals and UCB announce Phase III study of sodium oxybate in patients with fibromyalgia meets primary endpoints
Genzyme's Lemtrada Approved by the FDA

Poxvirus hijacks cell movement to spread infection
Giovanni_Battista_Amici

CHEMCON does it again: Flawless FDA Inspection
